yahoo_financeOriginal article
Stoke Therapeutics Completes Enrollment in Phase 3 Study of Zorevunersen for Dravet Syndrome Treatment
Phase 3ZorevunersenPositive
AI Analysis
Summary
Stoke Therapeutics has completed enrollment in a Phase 3 study of zorevunersen for the treatment of Dravet Syndrome. The milestone marks progression toward potential regulatory submission and approval.
Clinical Trial Data
Phase
Phase 3
Importance:6/10
Sentiment:
0.50
Phase 3enrollment completedDravet Syndromeclinical trial
Related Companies
Read the original article
Published by yahoo_finance on June 30, 2026 1:47 PM